Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses
Date:7/7/2008

opportunities. In addition, by selectively reducing cash pay debt,

Angiotech expects the remaining royalty revenue derived from its

partners BSC and Cook Group Incorporated ("Cook") will be adequate to

service any remaining debt. The various assets, including the royalty

business and API equity stake, owned by Angiotech will also allow

continued exploration of additional financing and strategic

alternatives to potentially further reduce or eliminate remaining

Angiotech debt.

Transaction Description and Plan

- Transaction Process. In late 2007 and early 2008, Angiotech

management and its Board of Directors discussed and reviewed various

financial and strategic alternatives, with the goal of evaluating and

pursuing selected opportunities to reduce debt, mitigate certain

risks and improve shareholder value. As a result of this review,

Angiotech conducted a process, together with its financial and legal

advisors, in which multiple potential investors were contacted to

evaluate an investment in API. Angiotech received and evaluated

multiple proposals over the past several months, and ultimately

concluded negotiations with Ares and New Leaf.

- Formation of API. API has been established as a Delaware corporation,

with principal executive offices in Vancouver, British Columbia.

Immediately prior to the close of the transaction, Angiotech and API

will enter into agreements to transfer to API certain assets and

liabilities of Angiotech, which primarily include the various

operating business assets and product development programs of

Angiotech, and exclude (i) intellectual property and royalty revenue

related to BSC's TAXUS paclitaxel-eluting coronary stent system; (ii)

potential royalty and other income from certain
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- According to a new market research report, ... (2015-2020), , published by Mordor Intelligence, the Global market is ... of 2020, with North America being ... the global market size. The Global market for Stem Cells ... the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) , ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation ... largest providers of post-acute healthcare services, offering both ... results of operations for the second quarter ended ... was characterized by strong volume growth in both ... EBITDA," said Jay Grinney, President and Chief Executive ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... announced its GHS Label Guide . To align chemical container labeling with ... guide includes explanations of label components, an example of an accurate label, and ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: INDV) ... naloxone nasal spray was accepted and received Priority Review ... the treatment of opioid overdose. This naloxone nasal spray ... formulated for optimal absorption into the nasal mucosa. 1 ... training so individuals may be better equipped to help ...
Breaking Biology Technology:Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34
... 4 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... - Thomson Financial 14th Anniversary NewsMakers in the ... accessed at, http://www.hgsi.com . (Logo: ... Genome Sciences, senior management team will present,an overview ...
... Colo., Sept. 4 Allos,Therapeutics, Inc. (Nasdaq: ... and commercialization of small molecule therapeutics for,the treatment ... President and,CEO, will present a corporate overview at ... York. The Company,s presentation will take place ...
... Model, Selection and Bias; Dr. Klaas Prins to Present on ... ... Using Metadata, MOUNTAIN VIEW, Calif., Sept. 4 ... and,strategic services for optimizing clinical drug development, today,announced that Pharsight ...
Cached Biology Technology:Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference 2Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007 2Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007 3
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... second quarter ended June 30, 2015.  Revenue ... decrease of 33% compared to $6.8 million in the same ... 2015 was $0.3 million, or $0.01 per diluted share, which ... the same period a year ago.  Lower ...
(Date:7/20/2015)... July 20, 2015  Acuity Market Intelligence,s latest ... Convergence of Commerce and Privacy" forecasts that between ... apps will be downloaded to smart mobile devices ... biometrics market is projected to generate more than ... the seven-year forecast period.    "Biometrics ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... most severe form of that group of diseases, affects 500 ... by a protozoan, Leishmania infantum, transmitted by sand fly bites. ... lead to death if no treatment is given. In the ... by infection. It acts as parasite reservoir for humans. Development ...
... that it has discovered a new class of ... infection. Biota has filed worldwide patents and selected ... for further preclinical development prior to human clinical ... need and already a billion-dollar market, with growing ...
... a medically important fungus, causing potentially life-threatening infections in ... major cause of respiratory allergy, and it is implicated ... thought to lack the ability to reproduce sexually, but ... that the fungus has a number of characteristics of ...
Cached Biology News:Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 2Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 3Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 4Biota makes major antiviral discovery 2Secret sex life of killer fungus? 2
... traps a wide variety of solvent vapors that ... glass condensation flask (GCF400) allows for the collection ... easy draining. Rapid cooling time minimizes waiting period., ... quick solvent changes , -50?C ...
... Protein Phosphatase-2A (PPase-2A) is a serine/threonine phosphatase ... is isolated as the heterodimer of 60kDa ... the ability to dephosphorylate the a-subunit of ... PPase-2A has broad substrate specificity and may ...
... high performance spectral scanning multimode reader ... the advanced SkanIt Software it offers ... discovery assay development. Varioskan provides unlimited ... fluorescence and photometric assays and a ...
... of solvent vapors that can contaminate and degrade vacuum ... the collection of liquid into a self contained jar ... Ultra low -104 o C temperature ... Digital Display of temperature ...
Biology Products: